CONTEXT: Sexual function is the health-related quality of life (HRQOL) domain most commonly impaired after prostate cancer treatment; however, validated tools to enable personalized prediction of erectile dysfunction after prostate cancer treatment are lacking. OBJECTIVE: To predict long-term erectile function following prostate cancer treatment based on individual patient and treatment characteristics. DESIGN: Pretreatment patient characteristics, sexual HRQOL, and treatment details measured in a longitudinal academic multicenter cohort (Prostate Cancer Outcomes and Satisfaction With Treatment Quality Assessment; enrolled from 2003 through 2006), were used to develop models predicting erectile function 2 years after treatment. A community-based cohort (community-based Cancer of the Prostate Strategic Urologic Research Endeavor [CaPSURE]; enrolled 1995 through 2007) externally validated model performance. Patients in US academic and community-based practices whose HRQOL was measured pretreatment (N = 1201) underwent follow-up after prostatectomy, external radiotherapy, or brachytherapy for prostate cancer. Sexual outcomes among men completing 2 years' follow-up (n = 1027) were used to develop models predicting erectile function that were externally validated among 1913 patients in a community-based cohort. MAIN OUTCOME MEASURES: Patient-reported functional erections suitable for intercourse 2 years following prostate cancer treatment. RESULTS: Two years after prostate cancer treatment, 368 (37% [95% CI, 34%-40%]) of all patients and 335 (48% [95% CI, 45%-52%]) of those with functional erections prior to treatment reported functional erections; 531 (53% [95% CI, 50%-56%]) of patients without penile prostheses reported use of medications or other devices for erectile dysfunction. Pretreatment sexual HRQOL score, age, serum prostate-specific antigen level, race/ethnicity, body mass index, and intended treatment details were associated with functional erections 2 years after treatment. Multivariable logistic regression models predicting erectile function estimated 2-year function probabilities from as low as 10% or less to as high as 70% or greater depending on the individual's pretreatment patient characteristics and treatment details. The models performed well in predicting erections in external validation among CaPSURE cohort patients (areas under the receiver operating characteristic curve, 0.77 [95% CI, 0.74-0.80] for prostatectomy; 0.87 [95% CI, 0.80-0.94] for external radiotherapy; and 0.90 [95% CI, 0.85-0.95] for brachytherapy). CONCLUSION: Stratification by pretreatment patient characteristics and treatment details enables prediction of erectile function 2 years after prostatectomy, external radiotherapy, or brachytherapy for prostate cancer.
CONTEXT: Sexual function is the health-related quality of life (HRQOL) domain most commonly impaired after prostate cancer treatment; however, validated tools to enable personalized prediction of erectile dysfunction after prostate cancer treatment are lacking. OBJECTIVE: To predict long-term erectile function following prostate cancer treatment based on individual patient and treatment characteristics. DESIGN: Pretreatment patient characteristics, sexual HRQOL, and treatment details measured in a longitudinal academic multicenter cohort (Prostate Cancer Outcomes and Satisfaction With Treatment Quality Assessment; enrolled from 2003 through 2006), were used to develop models predicting erectile function 2 years after treatment. A community-based cohort (community-based Cancer of the Prostate Strategic Urologic Research Endeavor [CaPSURE]; enrolled 1995 through 2007) externally validated model performance. Patients in US academic and community-based practices whose HRQOL was measured pretreatment (N = 1201) underwent follow-up after prostatectomy, external radiotherapy, or brachytherapy for prostate cancer. Sexual outcomes among men completing 2 years' follow-up (n = 1027) were used to develop models predicting erectile function that were externally validated among 1913 patients in a community-based cohort. MAIN OUTCOME MEASURES: Patient-reported functional erections suitable for intercourse 2 years following prostate cancer treatment. RESULTS: Two years after prostate cancer treatment, 368 (37% [95% CI, 34%-40%]) of all patients and 335 (48% [95% CI, 45%-52%]) of those with functional erections prior to treatment reported functional erections; 531 (53% [95% CI, 50%-56%]) of patients without penile prostheses reported use of medications or other devices for erectile dysfunction. Pretreatment sexual HRQOL score, age, serum prostate-specific antigen level, race/ethnicity, body mass index, and intended treatment details were associated with functional erections 2 years after treatment. Multivariable logistic regression models predicting erectile function estimated 2-year function probabilities from as low as 10% or less to as high as 70% or greater depending on the individual's pretreatment patient characteristics and treatment details. The models performed well in predicting erections in external validation among CaPSURE cohort patients (areas under the receiver operating characteristic curve, 0.77 [95% CI, 0.74-0.80] for prostatectomy; 0.87 [95% CI, 0.80-0.94] for external radiotherapy; and 0.90 [95% CI, 0.85-0.95] for brachytherapy). CONCLUSION: Stratification by pretreatment patient characteristics and treatment details enables prediction of erectile function 2 years after prostatectomy, external radiotherapy, or brachytherapy for prostate cancer.
Authors: Uwe H G Michl; Martin G Friedrich; Markus Graefen; Alexander Haese; Hans Heinzer; Hartwig Huland Journal: J Urol Date: 2006-07 Impact factor: 7.450
Authors: David C Miller; Stephen B Gruber; Brent K Hollenbeck; James E Montie; John T Wei Journal: J Natl Cancer Inst Date: 2006-08-16 Impact factor: 13.506
Authors: David F Penson; Dale McLerran; Ziding Feng; Lin Li; Peter C Albertsen; Frank D Gilliland; Ann Hamilton; Richard M Hoffman; Robert A Stephenson; Arnold L Potosky; Janet L Stanford Journal: J Urol Date: 2005-05 Impact factor: 7.450
Authors: David C Miller; John T Wei; Rodney L Dunn; James E Montie; Hector Pimentel; Howard M Sandler; P William McLaughlin; Martin G Sanda Journal: Urology Date: 2006-07 Impact factor: 2.649
Authors: Michael Pinkawa; Karin Fischedick; Branka Asadpour; Bernd Gagel; Marc D Piroth; Sandra Nussen; Michael J Eble Journal: Int J Radiat Oncol Biol Phys Date: 2007-09-12 Impact factor: 7.038
Authors: A V D'Amico; R Whittington; S B Malkowicz; D Schultz; K Blank; G A Broderick; J E Tomaszewski; A A Renshaw; I Kaplan; C J Beard; A Wein Journal: JAMA Date: 1998-09-16 Impact factor: 56.272
Authors: Hiram Alberto Gay; Jeff M Michalski; Daniel A Hamstra; John T Wei; Rodney L Dunn; Eric A Klein; Howard M Sandler; Chris Saigal; Mark Litwin; Deborah Kuban; Larry Hembroff; Peter Chang; Martin G Sanda Journal: Urology Date: 2013-10-16 Impact factor: 2.649
Authors: A Matthew; N Lutzky-Cohen; L Jamnicky; K Currie; A Gentile; D Santa Mina; N Fleshner; A Finelli; R Hamilton; G Kulkarni; M Jewett; A Zlotta; J Trachtenberg; Z Yang; D Elterman Journal: Curr Oncol Date: 2018-12-01 Impact factor: 3.677
Authors: Anne Holck Storås; Martin G Sanda; Montse Ferrer; Jon Håvard Loge; Alv A Dahl; Eivind A S Steinsvik; Ferran Guedea; Milada Cvancarova; Sophie D Fosså Journal: Clin Genitourin Cancer Date: 2014-01-03 Impact factor: 2.872
Authors: Aaron A Laviana; Zhiguo Zhao; Li-Ching Huang; Tatsuki Koyama; Ralph Conwill; Karen Hoffman; Michael Goodman; Ann S Hamilton; Xiao-Cheng Wu; Lisa E Paddock; Antoinette Stroup; Matthew R Cooperberg; Mia Hashibe; Brock B O'Neil; Sherrie H Kaplan; Sheldon Greenfield; David F Penson; Daniel A Barocas Journal: Eur Urol Date: 2020-02-22 Impact factor: 20.096